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Abstract 
Background: Topically delivered tenofovir (TFV) from intravaginal rings, tablets, or gels is being evaluated for HIV pre‑
vention. We previously demonstrated that TFV delivered vaginally by gel protected macaques from vaginal infection 
with SHIV. Here we investigated efficacy of the TFV gel against vaginal transmission of a TFV‑resistant SHIV containing 
the K65R mutation (SHIV162P3K65R) and its relationship to drug levels in vaginal tissues.
Results: SHIV162P3K65R shows approximately a 5‑fold reduction in susceptibility to TFV compared to wild‑type SHIV. 
Efficacy was evaluated in pig‑tailed macaques exposed vaginally twice‑weekly (up to 10 weeks) to SHIV162P3K65R 
30 min after receiving placebo (n = 6) or 1% TFV (n = 6) gel. Four of the six controls were infected after a median of 5 
exposures. In contrast, five of six macaques that received TFV gel remained uninfected after 20 vaginal SHIV162P3K65R 
exposures, resulting in an estimated efficacy of 75%. The mean intracellular TFV‑diphosphate (TFV‑DP) concentrations 
in vaginal lymphocytes 4 h after a single gel dose were found to be high (1,631 fmol/106 cells, range 492–3,847) and 
within the in vitro IC75 range (1,206 fmol/10
6 cells) for SHIV162P3K65R.
Conclusion: Both the modest resistance conferred by K65R and the high TFV‑DP exposure in vaginal lymphocytes, 
likely explain the observed protection. The findings in this model do not predict complete loss of protection by topi‑
cal TFV against vaginal exposure to HIV‑1K65R viruses and provide a tissue drug target for high efficacy. These data 
will facilitate the development of TFV delivery platforms that have high activity on both wild‑type and TFV‑resistant 
viruses.
Keywords: Pre‑exposure prophylaxis, HIV‑1 drug resistance, Tenofovir, Microbicides
© 2015 Dobard et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
As treatment programs for human immunodeficiency 
virus (HIV) expand, access to antiretroviral therapies 
continue to benefit persons infected with HIV, particu-
larly in Sub-Saharan Africa, the epicenter of the pan-
demic [1]. Research on HIV prevention through the use 
of oral or topical antiretroviral drugs has also accelerated 
to provide promising prevention options for uninfected 
persons to protect themselves from acquiring HIV. Oral 
emtricitabine (FTC) and tenofovir (TFV) disoproxil 
fumarate (TDF) administered daily has now been dem-
onstrated to effectively prevent HIV in men and women 
[2] and is now an approved HIV prevention medication 
in the USA. Likewise, various topical products that dose 
vaginal tissues with tenofovir are under development. 
These include vaginal gels or tablets, as well as intravagi-
nal rings formulated with TFV or its oral pro-drug TDF. 
A phase IIb clinical trial in South Africa (CAPRISA 004) 
demonstrated that a vaginal 1% TFV gel reduced acqui-
sition of HIV by an average of 39% and approximately 
54% in women who used the gel more than 80% of the 
time [3]. However, recent data released from a similar 
phase III trial in South Africa (FACTS 001) was unable 
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to show efficacy by TFV gel, likely due to low adherence 
by study participants [4]. While sub-analysis of this study 
demonstrated an ~55% protective effect amongst women 
identified as highly adherent, it is unclear if these data 
will support regulatory approval of this TFV-releasing 
product [4]. Implications of these results however, may 
include advancing the clinical development of other 
TFV-releasing topical products such as vaginal tablets or 
intravaginal rings that share the high biological efficacy 
of TFV gels but may be more desirable by women [5–7]. 
Previous pharmacokinetic studies have shown that 1% 
TFV gels, vaginal TFV tablets containing 10 mg of TFV, 
and intravaginal rings with either TFV or TDF all dose 
vaginal tissues with high concentrations of TFV-diphos-
phate, the pharmacologically active drug [6–8]. Further-
more, efficacy studies in macaques exposed vaginally to 
wild-type SHIV demonstrated high protection by both 
1% TFV gel and TDF intravaginal rings [7–9].
As in treatment, the use of topical TFV for preven-
tion raises drug resistance concerns for its potential to 
impact the efficacy of antiretroviral prophylaxis as TFV 
is a main component of first-line regimens used globally 
to treat persons infected with HIV [1]. A K65R mutation 
in the reverse transcriptase gene of HIV-1, which con-
fers low-level (~2–5 fold) resistance to TFV, has been 
documented in patients failing TFV-containing regi-
mens and may increase exposure of uninfected persons 
to TFV-resistant HIV-1K65R viruses. The K65R mutation 
is also observed in persons virologically failing while on 
stavudine (d4T)-containing therapy, a first-line regimen 
extensively implemented in early treatment programs in 
the developing world [10, 11]. Clinical studies can help 
define the impact of TFV-resistant virus on the efficacy 
of topical TFV products. However, prevention failures 
due to infection with a TFV-resistant virus are difficult to 
ascertain in humans because of the uncertainty on adher-
ence to product at the time of infection and the inabil-
ity to exclude acquired resistance post-infection, which 
requires early testing and is often not feasible. Further-
more, the K65R mutation is known to have a high fit-
ness cost to viral replication, and thus is often rapidly 
outgrown by the more fit wild-type virus [12–14]. The 
reversion of K65R can be facilitated by insufficient drug 
pressure through inconsistent product use and low sys-
temic TFV exposures, which could underestimate clinical 
K65R-related TFV failures.
Animal models conducted under well-controlled con-
ditions including consistent product dosing and chal-
lenge viruses with defined drug resistance profiles, can be 
utilized for assessing the impact of TFV-resistant viruses 
on the efficacy of topical TFV. The repeat low-dose (RLD) 
SHIV exposure macaque model is an established model 
of vaginal and rectal HIV transmission which predicted 
the prophylactic efficacy of oral FTC/TDF combination 
[15–18]. This model was further used to evaluate the effi-
cacy of FTC/TDF against drug-resistant SHIV contain-
ing either K65R or the emtricitabine-associated M184V 
mutation [13, 19]. Likewise, the vaginal transmission 
model demonstrated complete protection against wild-
type SHIV by vaginal 1% TFV gel when applied 30 min 
before challenge and ~74% protection when adminis-
tered 3 days prior to challenge [8, 9]. By linking efficacy 
to tissue drug levels following gel dosing, this model 
was the first to document the intracellular drug concen-
trations required for vaginal protection [8]. Analysis of 
TFV-diphosphate (TFV-DP) in vaginal lymphocytes, 
pointed to TFV-DP concentrations above the 95% inhibi-
tory concentration (IC95) as a good predictor for pro-
tection. This pharmacologic correlate of protection was 
further validated by the demonstration of high efficacy 
of TDF intravaginal rings against vaginal SHIV infection 
[7]. Here, we expand the use of the macaque model to 
evaluate the efficacy of topically delivered TFV from a gel 
against a TFV-resistant SHIV containing the K65R muta-
tion that recapitulates the resistance and fitness profile of 
HIV-1 with the K65R mutation.
Results
Efficacy of TFV gel against SHIV162P3K65R
Vaginal 1% TFV gel provided complete protection against 
wild-type SHIV162P3 when applied 30 min before virus 
challenge [9]. Figure  1 shows infection outcomes after 
a maximum of 20 challenges in macaques who received 
either placebo or 1% TFV gel 30  min before vaginal 
exposure to SHIV162P3K65R. Four of six macaques in 
the placebo group became infected after a median of 5 
challenges (at exposure 3, 5, 5, and 17). In contrast, five 
of six macaques in the TFV group remained SHIV nega-
tive as measured by both PCR and serology throughout 
the challenge period and 10-week washout. The break-
through infection in the TFV treatment group occurred 
at challenge 8. The efficacy of TFV gel was estimated 
at 75% based upon 4/6 infections in the control group 
compared to 1/6 in the TFV treated group. However, 
due to small group numbers and low transmissibility of 
SHIV162P3K65R (67% infection rate), the protective effect 
in animals treated with TFV gel and risk of infection 
between the two groups was not statistically significantly 
(p = 0.24, Fisher’s exact test).
Analysis of SHIV reverse transcriptase sequences at 
time of infection confirmed the presence of K65R in all 
infected animals (data not shown). The SHIV-infected 
breakthrough animal continued to receive 1% TFV gel 
treatment for up to 10 weeks after the first RNA detec-
tion. Figure  1b shows the kinetics of plasma viral repli-
cation in the breakthrough infection compared to the 4 
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controls. The peak viremia in the breakthrough infection 
(2.9 ×  106 vRNA copies/ml) was within the range seen 
in placebo controls (3.5 ×  105 to 1.7 ×  107 vRNA cop-
ies/ml), as was the area under the curve (5.4 ×  106 and 
2.7 × 106 copies/ml) over the first 10 weeks of infection 
(p  =  0.39), showing no difference in systemic viremia 
during acute infection.
Systemic drug absorption following vaginal dosing 
with 1% TFV gel
In line with earlier reports, overall plasma TFV lev-
els detected 30  min after vaginal TFV gel application 
(12.2  ng/ml; range  =  0–400  ng/ml) were low in all six 
TFV treated macaques (Fig. 2a) [8, 9]. Likewise, the pro-
portion of measureable TFV in plasma over the 10 week 
challenge period was relatively low, with only 41 of a 
total of 120 measurements (34%) above the limit of 
detection (Fig. 2b). Both the low systemic exposure and 
infrequent detection of TFV likely reflects the temporal 
changes in vaginal drug absorption associated with the 
menstrual cycle [8, 20, 21]. Interestingly, the mean TFV 
concentrations in the breakthrough infection macaque 
PLk (52 ng/ml) was higher than the levels seen in unin-
fected animals (4.6  ng/ml). However, we note that the 












































Fig. 1 Efficacy of TFV gel against SHIV162P3K65R. a Survival curves representing the cumulative percentage of uninfected macaques as a function 
of the number of challenges. After 20 SHIV162P3K65R exposures, challenges were stopped and animals were monitored for ten additional weeks for 
infection in the follow‑up period. b Breakthrough infections show no evidence of blunted viremia. Individual virus load kinetics of controls (black 
lines) and breakthrough infection (red line) under continued twice‑weekly gel dosing. Time zero indicates the time of first SHIV RNA detection in 
plasma. Time zero indicates the time of first SHIV RNA detection in plasma. The dashed line denotes the limit of quantification of the virus load assay 
(50 copies/ml).
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TFV exposures in this macaque at and prior to the esti-
mated time of infection (challenge 8) was within the 
range of the protected animals, and thus the continued 
twice-weekly TFV dosing post-infection greatly contrib-
uted to the overall high TFV levels detected in this ani-
mal (Fig. 2b).
Intracellular TFV‑DP concentration in vaginal lymphocytes 
predict efficacy against TFV‑resistant SHIV
We previously documented in this model a strong asso-
ciation between intracellular TFV-DP levels in vaginal 
lymphocytes that exceeded the in  vitro IC95 and pro-
tection in  vivo, suggesting that TFV-DP levels in tar-
get cells is a good predictor of high efficacy against 
wild-type SHIV transmission. Similar analysis were 
performed to determine if the relationship between 
efficacy and tissue drug levels following TFV dosing 
also applies to protection against SHIV162P3K65R. We 
assessed the intracellular TFV-DP concentrations in 
vaginal lymphocytes purified from vaginal tissues 4  h 
after dosing macaques with 1% TFV gel and compared 
them to concentrations achieved in lymphocytes dosed 
in  vitro at TFV concentrations corresponding to the 
inhibitory concentrations (IC50–95) for SHIV162P3K65R. 
Data from seven macaques (4 current and 3 histori-
cal from a previous study [8]) showed that the median 
TFV-DP concentration in vaginal lymphocytes at 4  h 
was 1,631 fmol/106 cells (range = 492–3,847 fmol/106 
cells). In vitro dosing of PBMCs at TFV concentrations 
in range of the IC50 (12  µM), IC75 (60  µM), and IC95 
(300  µM) values for SHIV162P3K65R resulted in mean 
(±std dev) intracellular TFV-DP levels of 320  ±  141, 
1,206 ± 235 and 4,559 ± 2,867 fmol/106 cells, respec-
tively. These data show that in  vivo TFV-DP levels 
were closest to the IC75 concentrations which is con-
sistent with the observed 75% protection found in 
this study. These data are in agreement with previ-
ous findings against wild-type SHIV162P3 and pro-
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Fig. 2 Systemic drug exposure following vaginal TFV gel dosing. a Cumulative plasma TFV levels in macaques following twice‑weekly dosing over 
the 10 week challenge period. b Longitudinal assessment of individual plasma TFV levels in macaques at time of each SHIV challenge (30 min post 
gel dosing). TFV concentrations (LLOD = 3 ng/ml) are shown in black and red for uninfected and infected macaques, respectively. Shaded gray bar 
indicates estimated time of infection.
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Discussion
HIV treatment programs with regimens containing either 
TDF or d4T have the potential to enrich for TFV-resist-
ant HIV-1 containing the K65R mutation among persons 
experiencing virologic failure on these regimen, thus rais-
ing questions about efficacy of topical TFV products for 
prevention among uninfected persons exposed to such 
viruses [6, 7, 11]. Here, we show in a macaque model 
that TFV delivered by vaginal gel maintained protec-
tion against a SHIV isolate with the K65R mutation that 
shares the same TFV resistance and replicative fitness 
profile with HIV-1K65R. We provide pharmacokinetic evi-
dence in support of efficacy by showing inhibitory intra-
cellular TFV-DP concentrations in vaginal lymphocytes 
within the in vitro IC75. Both the modest 5-fold resistance 
to TFV conferred by K65R and the high levels of TFV-DP 
in vaginal lymphocytes likely explain the observed pro-
tection in this model. These findings suggest other topical 
delivery platforms including intravaginal rings, tablets, or 
films that are capable of delivering TFV concentrations 
that exceed those achieved by vaginal gels will equally 
protect against both wild-type and TFV-resistant viruses.
We demonstrate that five of six macaques treated with 
vaginal TFV gel were uninfected compared to only two of 
six placebo gel controls. However, the inability to infect 
two controls together with the small group numbers 
(n = 6), resulted in insufficient power to draw statistically 
significant conclusions. The low in  vivo transmissibility 
of SHIV162P3K65R at virus doses that efficiently infect 
macaques with wild-type SHIV162P3 is consistent with 
the high fitness cost conferred by K65R and lower trans-
mission rate observed previously [12, 14]. The virus 
infectivity to virion particle ratio of SHIV162P3K65R 
was found to be ~17-fold lower than that of wild-type 
SHIV162P3, and increasing the challenge dose ten times 
in this study was helpful but not sufficient to achieve 
100% infection rate in the placebo group [8, 9]. Although 
K65R has been previously shown to rapidly revert to 
wild-type post-infection, we document persistence of 
K65R in all infected animals, likely the result of intro-
ducing two mutations (AAA) in the K65 codon versus 
the single nucleotide mutation often found in naturally 
emerging K65R mutations. These findings further sup-
port the use of this K65R isolate as a tool for executing 
TFV resistant transmission and prevention studies under 
well-controlled conditions [12].
We further showed that TFV was detected in plasma 
samples collected shortly after gel dosing, confirming 
rapid absorption through vaginal tissues. The low and 
infrequent systemic exposure of TFV in macaques fol-
lowing twice-weekly intravaginal dosing were similar to 
those detected in women who applied vaginal TFV gel 
twice-daily for 2  weeks (5.5  ng/ml) [22]. We also found 
no reduction in the acute viremia of the breakthrough 
infection compared to controls, reflecting insignificant 
antiviral activity due to nominal systemic TFV exposure 
by the continued twice-weekly gel dosing post infection.
The single-dose PK data were instrumental in link-
ing TFV-DP concentrations in vaginal lymphocytes 
to in  vitro activity and in  vivo protection against 
SHIV162P3K65R. It is plausible that the tissue concentra-
tions may have slightly increased during the challenge 
period due to accumulation of TFV-DP by repeat twice-
weekly gel dosing, underscoring the need to achieve high 
mucosal tissue levels to fully protect against TFV-resist-
ant viruses. As interest increases in exploring alternative 
delivery platforms capable of administering TFV prod-
rugs that achieve even higher vaginal tissue concentra-
tions of TFV-DP because of sustained release or more 
efficient dosing, it is expected that such products may 
further enhance protection against TFV-resistant virus 
[5–7, 23]. The protective tissue drug levels defined in this 
study will help inform these studies. We also note that 
while our results address the efficacy against low-level 
TFV resistance mediated by K65R, our findings may have 
broader implications on mutant viruses with a similar 
level of TFV resistance conferred by other mutations as 
seen clinically with multiple thymidine analog mutations.
Conclusions
We show in a repeat challenge model that 1% TFV gel 
maintained protection against vaginal infection with a 
TFV-resistant SHIV and provide pharmacokinetic sup-
port for this protection. These findings are reassuring, 
particularly for regions with prevalent HIV-1 with the 
K65R mutation. This macaque model of pharmacokinet-
ics and efficacy against vaginal SHIV162P3K65R infection 
will help inform the development of improved topi-
cal TFV products that may have higher and more dura-
ble efficacy against TFV-resistant isolates and are more 




(TFV) was kindly provided by Gilead Sciences; 1% TFV 
(wt/wt) was formulated in 2% hydroxyethyl cellulose 
(HEC) gel as previously described [8, 9]. Gels were for-
mulated at pH 6.5 to mimic the average vaginal pH of 
pigtailed macaques [21]. A matching placebo 2% HEC gel 
was used as a control.
Virus stocks
The wild-type SHIV162P3 and SHIV162P3K65R virus 
stocks used were generated as described elsewhere [14]. 
The K65R substitution in SHIV162P3 confers ~5-fold 
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reduction in susceptibility to TFV and was introduced by 
site-directed mutagenesis with two nucleotide changes 
(AAA →  CGA) to minimize reversion of K65R in  vivo 
[13]. Virus titer of challenge stocks was calculated in 
macaque PBMCs and diluted to 500 tissue culture infec-
tive dose (500 TCID50) and stored separately in 1-ml ali-
quots in liquid nitrogen. Individual vials were thawed on 
ice prior to each challenge.
Measurement of drug concentrations in plasma, vaginal 
lymphocytes, and peripheral blood mononuclear cells 
(PBMCs)
TFV concentrations in plasma were measured in 
macaques 30 min after vaginal administration of TFV gel, 
resulting in the analysis of 20 samples from each of the 
6 macaques (120 total). Briefly, TFV was extracted from 
100  µl of plasma by protein precipitation with 500  µl 
of methanol containing 200  ng of 13C-labeled TFV as 
internal standard. Supernatant containing the drug from 
precipitation was evaporated to near dryness under vac-
uum and then re-suspended in HPLC buffer containing 
9.9 mM of acetic acid, 5.9 mM of ammonium hydroxide, 
and 9.4  mM of formic acid (pH ~3). Drug levels were 
analyzed by using liquid chromatography–mass spec-
trometry (LC–MS) [8, 24]. The assay had a lower limit of 
quantification (LLOQ) of 3 ng/ml and standard curve R2 
values greater than 0.99.
We previously documented high intracellular TFV-
DP concentrations in lymphocytes collected from vagi-
nal tissues in macaques (n =  3) sacrificed 4 h following 
a single dose of vaginal 1% TFV gel [8]. To expand these 
data, we additionally measured TFV-DP levels in vaginal 
lymphocytes in SHIV-infected macaques (n  =  4) sacri-
ficed 4 h after receiving a single vaginal dose of 1% TFV 
gel. All tissue collection and processing procedures were 
conducted by the same veterinarian pathologists, labo-
ratory technicians, and using the same tissue digestion 
and mononuclear cell enrichment protocols as described 
in the previous study [8]. Briefly, vaginal tissue collected 
at time of necropsy was dissociated using enzyme cock-
tails and lymphocyte purification procedures. Total cell 
populations were gated and counted for mononuclear 
cells using a Muse Cell counter with CytoSoft Data 
Acquisition and Analysis Software (Millipore, Billerica, 
MA). Intracellular TFV-DP concentrations in vaginal 
lymphocytes were measured with an automated online 
weak anion exchange solid-phase extraction method 
coupled with ion-pair chromatography–MS/MS [24]. 
TFV-DP levels were expressed as femtomoles (fmol) per 
million cells with a lower limit of quantitation (LLOQ) of 
2.5 fmol/sample.
To compare TFV-DP concentrations observed in  vivo 
with those achieved in  vitro, macaque PBMCs were 
incubated with varying concentrations of TFV and intracel-
lular TFV-DP concentrations were measured at each dose. 
Briefly, PBMCs (5.0 × 106) were incubated 2–4 h in RPMI 
media containing TFV concentrations within the range of 
the 10–99% inhibitory concentrations (IC10–99) [300, 60, 12, 
2.4, 0.48, 0.096 µM] for wild-type and SHIV162P3K65R virus 
[8, 13]. Following incubation, cells were washed extensively 
with saline buffer solution, pelleted, and lysed in 1 ml of ice 
cold 80% MeOH. Intracellular TFV-DP levels were meas-
ured as described above.
Efficacy of 1% TFV gel in preventing vaginal transmission 
of SHIV162P3K65R
The efficacy of TFV gel against vaginal transmission 
of SHIV162P3K65R was evaluated in female pig-tailed 
macaques under conditions similar to those described for 
wild-type SHIV162P3 [8, 9]. Macaques received 3 ml of 
intravaginal placebo (n = 6) or 1% TFV (n = 6) gel 30 min 
before each vaginal exposure to SHIV162P3K65R. Chal-
lenges were performed twice per week (every 3–4 days) 
for 10  weeks or up to 20 exposures. Vaginal challenges 
were administered by atraumatic inoculation of 1  ml of 
SHIV162P3K65R (500 TCID) into the vaginal vault. The 
challenge dose was increased ~10 times higher than wild 
type SHIV162P3 (from 50 to 500 TCID50) to adjust for 
the lower transmissibility SHIV162P3K65R [8, 9, 12, 14]. 
Blood was collected 30 min after each gel application to 
monitor for SHIV infection and plasma drug levels. SHIV 
infection was determined by monitoring SHIV RNA in 
plasma by RT-PCR [8]. The estimated time of infection 
was defined as 7  days (two challenges) prior to SHIV 
positive to account for the eclipse period between virus 
inoculation and detection of SHIV RNA in plasma [25]. 
Animals were considered protected if they tested nega-
tive for SHIV plasma RNA and SHIV DNA in PBMCs 
and remained seronegative during the course of the study 
and the following 10  weeks of washout in the absence 
of challenge and gel application. All experiments were 
done under highly controlled conditions by the same 
personnel, using the same virus stock, and procedures 
as described in previous studies [8, 9, 20]. These studies 
adhered to the Guide for the Care and Use of Labora-
tory Animals (Institute for Laboratory Animal Research, 
1996); all procedures were approved by the Institutional 
Animal Care and Use Committees (IACUC) of both the 
Centers for Disease Control and Prevention (CDC) and 
the Yerkes National Primate Research Center (Emory 
University).
Statistical analysis
The cumulative probability of macaques remaining 
uninfected after repeated low-dose viral exposures 
was computed and graphically displayed using the 
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product limit (Kaplan–Meier) estimator. The log-rank 
test statistic was used to non-parametrically compare 
survival curves between the control and treatment 
groups. Uninfected macaques were right censored at 
the maximal exposure number (20 exposures). Inter-
vention efficacy was calculated as 1 −  (p1/p0), where 
p1 and p0 denote the proportion of infections for 
intervention and control animals, respectively. Acute 
RNA viremias were compared using the Wilcoxon 
rank-sum test.
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